

Telefax



**Boehringer
Ingelheim**

Examiner Carlos A. Azpuru
U. S. Patent and Trademark Office

Boehringer Ingelheim
Corporation

703/308-4734

Page 1 of 21

April 10, 2003

Re: USSN 09/975,418; Attorney Docket No. 1/1149

Philip I. Datlow
Telephone 203/798-4542
Telefax 203/798-4408
E-Mail
pdatlow@rdg.boehringer-
ingelheim.com

Dear Examiner Azpuru:

Enclosed herewith please find the following documents for the above-referenced patent application:

900 Ridgebury Rd/P.O. Box 368
Ridgefield, CT 06877-0368

1. Amendment Under 37 CFR §1.312 (10 Pages)
2. Fee Transmittal for FY 2003 (3 Pages)
3. Copy of Claims from USSN 09/961,822; Attorney Docket No. 1/1148

Sincerely,

Philip I. Datlow
Attorney for Applicant(s)
Reg. No. 41,482

US Appln. No. 09/975,418
AMENDMENT UNDER 37 CFR 1.312

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bechtold-Peters, et al.

Allowed: February 6, 2003

Application No.: 09/975,418

Group Art Unit: 1615

Confirmation No.: 4479

Filed: 10/11/2001

Examiner: C. Azpuru

Docket No. 1/1149

For: INHALABLE POWDER CONTAINING TIOTROPIUM

AMENDMENT UNDER 37 C.F.R. §1.312

BOX ISSUE FEE

Commissioner for Patents
Washington, D.C. 20231

Sir:

The fees due hereunder are set out on the enclosed Fee Transmittal for FY 2003 filed in triplicate. The Commissioner is hereby authorized to charge this and any other fee which may be required, and to credit any overpayment, to Deposit Account No. 02-2955.

Pursuant to the provisions of 37 C.F.R. §1.312, please amend the above-captioned application in the following manner: